Home > Healthcare > Pharmaceuticals > Finished Drug Form > Aminophylline Market

Aminophylline Market Trends

Report ID: GMI9210
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Aminophylline Market Trends

Growing government approvals along with the increasing advancements in personalized medicine as well as technological innovation are few factors that are significantly propelling the market demand.
For instance, in November 2022, AstraZeneca's PT027, a pioneering pressurized metered-dose inhaler (pMDI) containing aminophylline, received a positive recommendation from the FDA Advisory Committee, positioning it as a potential asthma treatment. AstraZeneca's recent rebranding of PT027 as Airsupra (albuterol/budesonide) signified a healthcare milestone, as it marked the approval of the first and only rescue medication in the U.S. capable of reducing the risk of asthma exacerbations, offering renewed hope and improved options for asthma patients.
Furthermore, despite its efficacy in treating respiratory conditions, aminophylline can lead to side effects such as nausea, vomiting, palpitations, and seizures, which may limit its widespread adoption. Thus, concerns regarding safety and tolerability may deter healthcare providers and patients from utilizing aminophylline, thereby hindering market expansion to a certain extent.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Aminophylline market size was USD 291.2 million in 2023 and is expected to register 2.1% CAGR from 2024-2032 owing to its widespread use in the treatment of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and several other respiratory diseases.

Aminophylline industry from the injection segment recorded USD 166.3 million in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to offering a rapid onset of action and precise dosing, making them preferred in acute situations such as severe asthma exacerbations.

The U.S. aminophylline industry held 92.1% share in 2023 and is expected to register a commendable CAGR from 2024-2032 due to growing respiratory disease condition, rising precision medicine and patient-centric therapies in the country.

Cipla, Cooper S.A., GSK plc, Glenmark Pharmaceuticals Ltd., Inopha International Co, Limited, Johnson & Johnson Pvt. Ltd., Lupin, Pfizer Inc., S.A.L.F. S.p.A. Laboratorio Farmacologico, Teva Pharmaceuticals Industries Ltd., are some of the major aminophylline companies worldwide.